Searched for
ZYDUS LIFE SHARES
Scanning cancer, up close & personal: A revolution is underway in cancer diagnosisA gene-based test called next-generation sequencing can identify precise mutations, which can then be treated with targeted therapies. Sinc...- Stocks in news: Prime Focus, Groww, GIC RE, Wipro, NykaaIndian benchmark indices traded with a positive bias, with the Nifty consolidating near the 24,000 mark and closing near its day's high. Se...
- Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...
- From Tata to tech giants, Indian companies tighten grip on UK economyIndian businesses are significantly expanding their UK presence, with company numbers soaring by nearly 60% and combined revenues exceeding...
- Stocks in news: RIL, Coal India, IDFC First Bank, Zydus Life, ONGCMarkets traded subdued with the India VIX correcting nearly 15% this week, though this hasn't significantly impacted benchmark index moveme...
- Zydus Lifesciences hikes share buyback price to Rs 1,260 per share, lowers share countZydus Lifesciences increased its share buyback price to Rs 1,260 per share while reducing the repurchase size to 87.3 lakh shares. The tota...
- For both the compulsive trader and careful investor: 25 stocks to watch if risk appetite returns; some with upside potential, some notIf the price of crude oil softens, Indian equities may again see a risk-on phase. Tariff concerns are no longer the central issue; the larg...
- Bond yields, FIIs and corporate actions among 8 factors to steer D-Street this weekNifty closed marginally higher last week, driven by IT and energy stocks, as markets brace for key events. Technical analysts suggest Nifty...
- Stocks in news: Lenskart, Apollo Hospitals, ZEE, BPCL, HindalcoIndian markets navigated a sideways trend, with analysts urging caution until the 24,000 mark is reclaimed. Key stocks like Lenskart, Apoll...
- Two Trades for Today: A top life insurer for a gain of 7.8%, a mid-cap pharma stock for a rise of almost 6%Our technical analysts identify select stocks every trading day that may gain momentum even in volatile markets. Here are the technical cal...
- Stocks in news: HAL, TMPV, Bharti Airtel, Anant Raj, Zydus Life, Tata MotorsIndian markets experienced a volatile yet stable session after a sharp sell-off, with the Nifty showing resilience. Key companies like HAL,...
- Zydus settles US Mirabegron patent dispute with Astellas for $120 millionZydus Lifesciences and its US subsidiary have settled patent litigation with Astellas Pharma over Astellas' Myrbetriq. Zydus will pay Astel...
- Zydus Lifesciences shares in focus after USFDA nod for Verapamil Hydrochloride ER TabletsZydus Lifesciences will be in focus on Wednesday after receiving final USFDA approval for its Verapamil Hydrochloride Extended-Release Tabl...
- Zydus Lifesciences shares in focus on USFDA nod for canine drugShares of Zydus Lifesciences are likely in focus after its subsidiary, ZyVet Animal Health, launched the first FDA-approved generic treatme...
- Zydus Lifesciences shares in focus on licensing deal with Synthon for generic ZEPOSIA in US marketZydus Lifesciences signed an exclusive licensing and supply deal with Netherlands-based Synthon BV to commercialize generic Ozanimod Capsul...
- Zydus Lifesciences shares rally 3% after FDA approval for prostate cancer drugZydus Lifesciences received final USFDA approval to manufacture Apalutamide tablets for prostate cancer, following last week's approval for...
- Zydus Life shares rise 2% after USFDA nod for Eluxadoline tabletsZydus Lifesciences shares rose nearly 2% to Rs 899.40 after receiving USFDA approval to manufacture Eluxadoline Tablets (75 mg & 100 mg) fo...
- Hold Zydus Lifesciences, target price Rs 1,090: JM FinancialJM Financial maintains a hold rating on Zydus Lifesciences, setting a target price of Rs 1,090. The quarterly income has dropped by 15.40% ...
- Jefferies upgrades Zydus Life to 'Buy' on strong US pipeline potential, stock up 4%Global brokerage firm Jefferies has upgraded Zydus Lifesciences to a 'Buy' rating, citing the strength of the company’s US pipeline as a ma...
- Buy Zydus Lifesciences, target price Rs 530: Yes SecuritiesBullish ABC breakout suggests follow through moves on P&F chart.
Load More
